Promising results in terms of MI and stroke risk reduction have been instead demonstrated with the SGLT1/2 inhibitor sotaglifozin [47, 48], with a benefit similar to what observed with GLP1Ras but with the advantage of an additional proved reduction in HF-related hospitalization. The gene discussed is SLC5A1; the disease is hydrops fetalis.